Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

High serum vitamin D protects against renal dysfunction due to cadmium exposure

16 Apr 2018
Kidney failures and organ donors: Singapore

High serum levels of 25-hydroxyvitamin D (25(OH)D) appear to reduce the risk of renal tubular dysfunction in individuals exposed to cadmium, a recent study has shown.

The study included 133 adults born in two cadmium-polluted areas and one control area. Cadmium levels in urine (UCd) and blood (BCd) were measured, along with urinary β2Microglobulin (UBMG), urinary creatinine (UCr), urinary retinol binding protein (URBP) and serum 25(OH)D.

There was a significant and inverse association between serum 25(OH)D and UBMG and URBP (p<0.05). Participants with serum 25(OH)D levels ≥40 ng/mL were less likely to have renal dysfunction when either UBMG (odds ratio [OR], 0.20; 95 percent CI, 0.1–0.8) or URBP (OR, 0.28; 0.1–1.1) was used as indicators. Serum 25(OH)D <30 ng/mL was used as reference.

A similar trend was observed when analysis was restricted to participants with high UCd or BCd concentrations.

Using UBMG as a marker, researchers showed that those with UCd ≥3.0 µg/g Cr but serum 25(OH)D ≥40 ng/mL had significantly lower risks of renal dysfunction (OR, 0.23; 0.1–0.9). In participants with BCd ≥2.0 µg/L, high serum levels of 25(OH)D also correlated significantly with reduced UBMG (OR, 0.19; 0.1–0.8).

The trends for both high-UCd and high-BCd patients were similar when using URBP as an indicator of renal dysfunction, but the effects were not statistically significant.

“[T]he [protective] effects of vitamin D against cadmium-induced renal dysfunction may be due to its role on oxidative stress and inflammatory reaction,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.